Dermira Inc (NASDAQ:DERM) dropped 9.5% during mid-day trading on Thursday . The company traded as low as $9.21 and last traded at $9.29. Approximately 1,745,326 shares traded hands during mid-day trading, an increase of 4% from the average daily volume of 1,684,922 shares. The stock had previously closed at $10.26.
DERM has been the topic of a number of recent research reports. BidaskClub raised Dermira from a “hold” rating to a “buy” rating in a research report on Tuesday, January 30th. Cantor Fitzgerald set a $45.00 target price on Dermira and gave the company a “buy” rating in a research report on Monday, January 15th. Guggenheim reissued a “buy” rating and issued a $30.00 target price on shares of Dermira in a research report on Thursday, December 14th. Mizuho dropped their target price on Dermira from $43.00 to $39.00 and set a “buy” rating on the stock in a research report on Tuesday, December 12th. Finally, Cowen set a $25.00 target price on Dermira and gave the company a “buy” rating in a research report on Monday, March 5th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $32.71.
The stock has a market cap of $388.53, a PE ratio of -1.24 and a beta of 0.86. The company has a debt-to-equity ratio of 1.87, a current ratio of 5.28 and a quick ratio of 5.28.
Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($0.09). The company had revenue of $1.34 million for the quarter, compared to analyst estimates of $1.10 million. Dermira had a negative return on equity of 62.07% and a negative net margin of 6,678.29%. sell-side analysts expect that Dermira Inc will post -4.66 EPS for the current year.
In other Dermira news, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $27.05, for a total transaction of $499,288.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $28.55, for a total value of $85,650.00. Following the transaction, the insider now directly owns 5,802 shares in the company, valued at $165,647.10. The disclosure for this sale can be found here. Insiders have sold a total of 29,758 shares of company stock worth $810,479 in the last ninety days. Insiders own 13.30% of the company’s stock.
Several hedge funds have recently bought and sold shares of DERM. Millennium Management LLC acquired a new position in shares of Dermira during the 4th quarter worth approximately $25,084,000. Franklin Resources Inc. acquired a new position in shares of Dermira during the 4th quarter worth approximately $24,820,000. Point72 Asset Management L.P. increased its holdings in shares of Dermira by 621.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 712,904 shares of the biopharmaceutical company’s stock worth $19,248,000 after acquiring an additional 614,138 shares during the last quarter. Emerald Advisers Inc. PA acquired a new position in shares of Dermira during the 4th quarter worth approximately $14,918,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Dermira during the 3rd quarter worth approximately $3,107,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Dermira (DERM) Shares Down 9.5%” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/03/17/dermira-derm-shares-down-9-5.html.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.